Beyond anti-TNF-α agents in psoriatic arthritis

Evaluation of: McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, Phase II proof-of-concept trial. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202646 (2013) (Epub ahead of print).